These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 9929144

  • 1. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
    Masunaga S, Ono K, Hori H, Akaboshi M, Kawai K, Suzuki M, Kinashi Y, Kasai S, Nagasawa H, Uto Y.
    Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Int J Hyperthermia; 2005 Jun; 21(4):305-18. PubMed ID: 16019857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination and drug modification assessed by micronucleus frequency assay of potentially lethal damage repair in quiescent cell populations within murine solid tumors.
    Masunaga S, Ono K, Akaboshi M, Takagaki M, Kinashi Y, Suzuki M, Abe M.
    Radiat Med; 1997 Jun; 15(1):37-43. PubMed ID: 9134583
    [Abstract] [Full Text] [Related]

  • 8. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Ohnishi K, Takahashi A, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
    [Abstract] [Full Text] [Related]

  • 9. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S, Sakurai Y, Suzuki M, Nagata K, Maruhashi A, Kinash Y, Ono K.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):920-7. PubMed ID: 15465210
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
    Masunaga S, Ono K, Takahashi A, Ohnishi K, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Nagasawa H, Uto Y, Hori H.
    Cancer Sci; 2003 Jan 01; 94(1):125-33. PubMed ID: 12708486
    [Abstract] [Full Text] [Related]

  • 11. Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells.
    Masunaga S, Ono K, Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S, Nagasawa H, Uto Y.
    Int J Hyperthermia; 1999 Jan 01; 15(1):7-16. PubMed ID: 10193753
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells.
    Masunaga SI, Ono K, Suzuki M, Kinashi Y, Takagaki M, Hori H, Kasai S, Nagasawa H, Uto Y.
    Jpn J Cancer Res; 2000 May 01; 91(5):566-72. PubMed ID: 10835503
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Change in oxygenation status in intratumour total and quiescent cells following gamma-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment.
    Masunaga S, Ono K, Hori H, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y.
    Br J Radiol; 2000 Sep 01; 73(873):978-86. PubMed ID: 11064652
    [Abstract] [Full Text] [Related]

  • 15. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy.
    Masunaga S, Nagasawa H, Hiraoka M, Sakurai Y, Uto Y, Hori H, Nagata K, Suzuki M, Maruhashi A, Kinashi Y, Ono K.
    Anticancer Res; 2004 Sep 01; 24(5A):2975-83. PubMed ID: 15517904
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of apoptosis and micronucleation induced by reactor neutron beams with two different cadmium ratios in total and quiescent cell populations within solid tumors.
    Masunaga S, Ono K, Sakurai Y, Takagaki M, Kobayashi T, Kinashi Y, Suzuki M.
    Int J Radiat Oncol Biol Phys; 2001 Nov 01; 51(3):828-39. PubMed ID: 11697329
    [Abstract] [Full Text] [Related]

  • 19. Effects of p53 status and wortmannin treatment on potentially lethal damage repair, with emphasis on the response of intratumor quiescent cells.
    Masunaga S, Takahashi A, Ohnishi K, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Radiat Med; 2003 Nov 01; 21(3):120-7. PubMed ID: 12868860
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.
    Masunaga S, Tano K, Watanabe M, Kashino G, Suzuki M, Kinashi Y, Ono K, Nakamura J.
    Br J Radiol; 2009 May 01; 82(977):392-400. PubMed ID: 19153181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.